(HealthDay News) — For patients with obstructive sleep apnea (OSA) and suboptimally controlled type 2 diabetes, use of continuous positive airway pressure (CPAP) for 6 months is associated with improved glycemic control and insulin resistance, according to a study published in the American Journal of Respiratory and Critical Care Medicine.
Elisabet Martínez-Cerón, from the Hospital Universitario La Paz in Madrid, and colleagues examined the effect of CPAP on HbA1c levels in patients with suboptimally controlled type 2 diabetes and OSA. Fifty patients with type 2 diabetes and OSA were randomized to CPAP (26 participants) or no CPAP (control, 24 participants) in a 6-month clinical trial; their usual diabetes medications remained unchanged.
The researchers found that the CPAP group achieved a greater decrease in HbA1c levels compared with the control group after 6 months. Compared with the control group, the CPAP group also had improved insulin resistance and sensitivity measures (in noninsulin users) and improved serum levels of interleukin (IL)-1β, IL-6, and adiponectin after six months. Mean nocturnal oxygen saturation and baseline IL-1β were independently related to 6-month change in HbA1c levels in patients treated with CPAP (P=.002).
“Among patients with suboptimally controlled type 2 diabetes and OSA, CPAP treatment for 6 months, when compared to a control group, resulted in improved glycemic control and insulin resistance,” the researchers wrote.